

Publikationen 2001

Angheliescu I, Germeyer S, Müller MJ, Klawe C, Singer P, Dahmen N, Wetzel H, Himmerich H, Szegedi A (2001) No association between the dopamine D₂ receptor taq1 A1 allele and earlier age of onset of alcohol dependence according to different specified criteria. *Alcohol Clin Exp Res* 25: 805-809

Angheliescu I, Klawe CJ, Bartenstein P, Szegedi A (2001) Normal PET after long-term ECT. *Am J Psychiatry* 158: 1527

Angheliescu I, Klawe C, Himmerich H, Szegedi A (2001) Topiramate in venlafaxine-induced visual hallucinations in an obese patient with a posterior cerebral artery infarction. *J Clin Psychopharmacol* 21: 462-464

Böhme I, Lüddens H (2001) The inhibitory neural circuitry as target of antiepileptic drugs. *Curr Med Chem* 8: 1257-1274

Connemann BJ, Mann K, Pascual-Marqui RD, Röschke J (2001) Limbic activity in slow wave sleep in a healthy subject with alpha-delta sleep. *Psychiatry Res* 107: 165-171

Dahmen N (2001) Pharmakotherapie psychopathologischer Veränderungen im Rahmen der multiplen Sklerose. In: ZETTL UK, MIX E (Hrsg) *Multiple Sklerose*. Springer, Berlin. S. 243-250

Dahmen N, Bierbrauer J, Kasten M (2001) Increased prevalence of obesity in narcoleptic patients and relatives. *Eur Arch Psychiatry Clin Neurosci* 251: 85-89

Dahmen N, Kasten M (2001) REM-associated hallucinations and sleep paralysis are dependent on body posture. *J Neurol* 248: 423-424

Dahmen N, Müller MJ, Germeyer S, Rujescu D, Angheliescu I, Hiemke C, Wetzel H (2001) Genetic polymorphisms of the dopamine D₂ and D₃ receptor and neuroleptic drug effects in schizophrenic patients. *Schizophr Res* 49: 223-225

Dauids E, Hopf HC (2001) Rasch progrediente infra- und supratentorielle zentralnervöse Symptomatik. *Akt Neurol* 28: 89-92

Erb C, Troost J, Kopf S, **Schmitt U**, Loffelholz K, Soreq H, Klein J (2001) Compensatory mechanisms enhance hippocampal acetylcholine release in transgenic mice expressing human acetylcholinesterase. *J Neurochem* 77: 638-646

Fehr C, Dahmen N, Klawe C, Eicke M, Szegedi A (2001) Piracetam in the treatment of tardive dyskinesia and akathisia: a case report. *J Clin Psychopharmacol* 21: 248-249

Fehr C, Schleicher A, Szegedi A, Angheliescu I, Klawe C, Hiemke C, Dahmen N (2001) Serotonergic polymorphisms in patients sufferings from alcoholism, anxiety disorders and narcolepsy. *Prog Neuropsychopharmacol Biol Psychiatry* 25: 965-982

Gencik M, **Dahmen N**, Wiecek S, **Kasten M**, Bierbrauer J, **Angelescu I**, **Szegedi A**, Menezes Saecker AM, Epplen JT (2001) A prepro-orexin gene polymorphism is associated with narcolepsy. *Neurology* 56: 115-117

Gencik M, **Dahmen N**, Wiecek S, **Kasten M**, Gencikova A, Epplen J (2001) ApoE polymorphisms in narcolepsy. *BMC Medical Genetics* 2: 9

Grözinger M, **Fell J**, **Röschke J** (2001) Neural net classification of REM sleep based on spectral measures as compared to nonlinear measures. *Biol Cybern* 85: 335-341

Gründer G, Siessmeier T, **Lange-Asschenfeldt C**, **Vernaleken I**, Buchholz HG, Stoeter P, Drzezga A, **Lüddens H**, Rosch F, Bartenstein P (2001) [18F]Fluoroethylflumazenil: a novel tracer for PET imaging of human benzodiazepine receptors. *Eur J Nucl Med* 28: 1463-1470

Gründer G, **Vernaleken I**, **Benkert O** (2001) Welche Eigenschaften machen Neuroleptikum „atypisch“? *Nervenarzt* 72: 833-843

Härtter S, Morita S, Bodin K, Ursing C, Tybring G, Bertilsson L (2001) Determination of exogenous melatonin and its 6-hydroxy metabolite in human plasma by liquid chromatography-mass spectrometry. *Ther Drug Monit* 23: 282-286

Härtter S, Ursing C, Morita S, Tybring G, von Bahr C, Christensen M, Rojdmarm S, Bertilsson L (2001) Orally given melatonin may serve as a probe drug for cytochrome P450 1A2 activity in vivo: a pilot study. *Clin Pharmacol Ther* 70: 10-16

Härtter S, WANG X, **Weigmann H**, Friedberg T, Arand M, Oesch F, **Hiemke C** (2001) Differential effects of fluvoxamine and other antidepressants on the biotransformation of melatonin. *J Clin Psychopharmacol* 21: 167-174

Henke M, Voderholzer U, **Dahmen N** (2001) Psychiatrische Aspekte des Rauchens. *Psycho* 27: 436-442

Hiemke C, Hoehn J, **Weigmann H**, Oehl W (2001) Auftreten von Nebenwirkungen unter Clozapin-Fluvoxamin-Kombination. In: NABER D; MÜLLER-SPAHN F (Hrsg). *Leponex*. Springer, Berlin. S. 133-138

Himmerich H, **Angelescu I**, **Klawe C**, **Szegedi A** (2001) Vitamin B12 and hepatic enzyme serum levels correlate in male alcohol-dependent patients. *Alcohol Alcohol* 36: 26-28

Himmerich H, **Müller MJ**, **Angelescu I**, **Klawe C**, **Wetzel H**, **Szegedi A** (2001) Beziehungen von biologischen Markern exzessiven Alkoholkonsums. *Suchtmed* 3: 67-72

Kaplan A, **Röschke J**, Darkhovsky B, **Fell J** (2001) Macrostructural EEG characterization based on nonparametric change point segmentation: application to sleep analysis. *J Neurosci Methods* 106: 81-90

Kapp-Steen G, Müller MJ, Schanz B, Schlösser R (2001) Patientenzufriedenheit mit der Behandlung in der Psychiatrischen Klinik der Johannes-Gutenberg Universität Mainz. *Psych Pflege* 7: 10-15

Lörch B, Mann K (2001) Ausbildung von Psychotherapeuten in Psychopharmakologie. *Praxis Klinische Verhaltensmedizin und Rehabilitation* 55: 211-216

Mann K, Benkert O (2001) Traum und Sexualität. In: Rüther E, Gruber-Rüther A, Heuser M (Hrsg). *Träume*. Verlag Integrative Psychiatrie. Innsbruck. S 9-17

Mann K, Pankok J, Leissner J, Benkert O (2001) Effects of moclobemide on sexual performance and nocturnal erections in psychogenic erectile dysfunction. *Psychopharmacology (Berl)* 156: 86-91

Mann K, Röschke J (2001) Heart rate variability during human sleep under the influence of pulsed high-frequency electromagnetic fields. In: EBEA 2001, 5th International Congress of the European BioElectromagnetics Association (EBEA). Finnish Institute of Occupational Health, Helsinki. pp 99-101

Mann K, Wagner P, Hiemke C, Frank C, Röschke J (2001) Nocturnal hormone profiles in healthy humans under the influence of pulsed high-frequency electromagnetic fields. In: Bartsch C; Bartsch H, Blak DE, Cardinali DP, Hrushesky WJM, Mecke D (eds) *The Pineal Gland Cancer*. Springer, Berlin. pp 541-550

Matsumoto I, Wilce PA, Buckley T, Dodd P, Puzke J, Spanagel R, Zieglgansberger W, Wolf G, Leng S, Rommelspacher H, Finckh U, **Schmidt LG** (2001) Ethanol and gene expression in brain. *Alcohol Clin Exp Res* 25, Suppl 5: 82S-86S

Möykkynen T, Uusi-Oukari M, Heikkila J, Lovinger DM, **Lüddens H**, Korpi ER (2001) Magnesium potentiation of the function of native and recombinant GABA(A) receptors. *Neuroreport* 12: 2175-2179

Müller MJ (2001) Die Beziehung profitiert signifikant. Eine ED-Pilotstudie untersuchte, ob sich Lebens- und Partnerschaftsqualität unter Sildenafil-Therapie verbessern. *Urologische Nachrichten; Zeitung für die Urologie* 08: 10

Müller MJ (2001) Exact tests for small sample 3x3 contingency tables with embedded fourfold tables: rationale and application. *German J Psychiatry* 4: 57-62

Müller MJ (2001) Klassifikationskonzepte und Behandlungsnotwendigkeit. *Psycho* 27: 144-149

Müller MJ (2001) Therapie der Minor Depression. *Psycho* 27: 3

Müller MJ, Benkert O (2001) Lower self-reported depression in patients with erectile dysfunction after treatment with sildenafil. *J Affect Disord* 66: 255-261

Müller MJ, Härtter S, Köhler D, Hiemke CH (2001) Serum levels of sulpiride enantiomers after oral treatment with racemic sulpiride in psychiatric patients: a pilot study. *Pharmacopsychiatry* 34: 27-32

Müller MJ, Ruof J, **Graf-Morgenstern M**, Porst H, Benkert O (2001) Quality of partnership in patients with erectile dysfunction after sildenafil treatment. *Pharmacopsychiatry* 34: 91-95

Müller MJ, **Schmidt LG** (2001) Quetiapin. *Arzneiverordnung in der Praxis AVP* 3: 7-8

Müller MJ, **Szegedi A** (2001) Definition und Diagnostik der Minor Depression. *Psycho* 27: 119

Müller MJ, **Szegedi A**, Wetzell H, Benkert O (2001) Depressive factors and their relationships with other symptom domains in schizophrenia, schizoaffective disorder, and psychotic depression. *Schizophr Bull* 27: 19-28

Narahashi T, Soderpalm B, Ericson M, Olausson P, Engel JA, Zhang X, Nordberg A, Marszalec W, Aistrup GL, **Schmidt LG**, Kalouti U, Smolka M, Hedlund L (2001) Mechanisms of alcohol-nicotine interactions: alcoholics versus smokers. *Alcohol Clin Exp Res* 25, Suppl 5: 152S-156S

Rao ML, **Hiemke C**, Grasmäder K, Baumann P (2001) Olanzapin: Pharmakologie, Pharmakokinetik und Therapeutisches Drug Monitoring. *Fortschr Neurol Psychiatr* 69: 510-517

Rappelsberger P, Trenker E, Rothmann Ch, Gruber G, Sykacek P, Roberts St, Klösch GK, Zeitlhofer J, Anderer P, Saletu B, Schlögl A, Värri A, Kemp B, Penzel Th, Herrmann W, Hasan J, Barbanof MJ, **Röschke J**, Kunz D, Dorffner G (2001) Das Projekt SIESTA. *Klin Neurophysiol* 32: 76-88

Rommelspacher H, Smolka M, **Schmidt LG**, Samochowiec J, Hoehe MR (2001) Genetic analysis of the μ -opioid receptor in alcohol-dependent individuals. *Alcohol* 24: 129-135

Ruof J, **Graf-Morgenstern M**, **Müller MJ** (2001) Lebensqualität bei Patienten mit erektiler Dysfunktion (ED). *Aktuel Urol* 32: 21-26

Schanz B, **Kapp-Steen G**, **Müller MJ** (2001) Patientenbefragung in der Psychiatrie. In: Satzinger W. *Patientenbefragung in Krankenhäusern: Konzepte, Methoden, Erfahrungen*. Asgard-Verlag Hippe, Sankt Augustin. S 259-265

Schirmacher R, Hamkens W, Piel M, **Schmitt U**, **Lüddens H**, **Hiemke C**, Rösch F (2001) Radiosynthesis of (\pm) -(2-((4-(2-[^{18}F]fluoro-ethoxy)phenyl)bis(4-methoxyphenyl)methoxy)ethyl)piperidine-3-carboxylic acid: a potential GAT-3 PET ligand to study GABAergic neuro-transmission *in vivo*. *Journal of Labelled Compounds and Radiopharmaceuticals* 44: 627-642.

Schlösser R, Brodie JD (2001) Brain imaging in psychiatry. In: HENN F, Sartorius N, Helmchen H, Lauter H (Hrsg) *Contemporary Psychiatry*. Vol. 1. Springer, Berlin. pp 179-207

Schmidt K, Nolte-Zenker B, Patzer J, Bauer M, **Schmidt LG**, Heinz A (2001) Psychopathological correlates of reduced dopamine receptor sensitivity in

depression, schizophrenia, and opiate and alcohol dependence. *Pharmacopsychiatry* 34: 66-72

Schmidt LG (2001) Alkoholkonsum an der Schwelle zum Missbrauch. *MMW Fortschr Med* 143: 20-22

Schmidt LG (2001) Moderne Therapie der Alkoholabhängigkeit. *Z Allg Med* 77: 112-117

Schmidt LG (2001) Pharmakotherapie der Tabakabhängigkeit. *Psycho* 27: 541-544

Schmidt LG (2001) Tabakabhängigkeit und ihre Behandlung. *Dt Ärztebl* 98: A1826-1833

Schmidt LG, SMOLKA M (2001) Relapse prevention in alcoholics by cigarette smoking? Involvement of nicotinic-dopaminergic mechanisms. *Alcohol* 24: 111-115

Schmitt U, **Lüddens H**, **Hiemke C** (2001) Behavioral analysis indicates benzodiazepine-tolerance mediated by the benzodiazepine binding-site at the GABA_A-receptor. *Prog Neuropsychopharmacol Biol Psychiatry* 25: 1145-1160

Schneider B, **Müller MJ**, Pilipp M (2001) Mortality in affective disorders. *J Affect Disord* 65: 263-274

Schneider B, Philipp M, **Müller MJ** (2001) Psychopathological predictors of suicide in patients with major depression during a 5-year follow-up. *Eur Psychiatry* 16: 283-288

Szegedi A (2001) Pharmakotherapie der Minor Depression. *Psycho* 27: 75-81

Szegedi A, **Schmidt LG** (2001) Delir: Diagnostik und Therapie. *AVP Arzneiverordnung in der Praxis* 4: 6-7

Weigmann H, **Gerek S**, **Zeisig A**, **Müller M**, **Härtter S**, **Hiemke C** (2001) Fluvoxamine but not sertraline inhibits the metabolism of olanzapine: evidence from a therapeutic drug monitoring service. *Ther Drug Monit* 23: 410-413

Weigmann H, **Härtter S**, **Fischer V**, **Dahmen N**, **Hiemke C** (2001) Kann der pharmakologisch aktive N-demethylierte Metabolit von Clozapin die Blut-Hirn-Schranke durchdringen? In: NABER D, MÜLLER-SPAHN F (Hrsg) *Leponex*. Springer, Berlin. S. 123-126

Weigmann H, **Härtter S**, Maehrlein S, Kiefer W, Krämer G, Dannhardt G, **Hiemke C** (2001) Simultaneous determination of olanzapine, clozapine and demethylated metabolites in serum by on-line column-switching high-performance liquid chromatography. *J Chromatogr B* 759: 63-71